New salmeterol/fluticasone MDI extends choice in asthma prescribing

Aloflute (salmeterol/fluticasone) metered dose inhaler is licensed for the treatment of asthma where use of a combination product is appropriate.

Patients should not be initiated on Aloflute during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma. | CAVALLINI JAMES/SCIENCE PHOTO LIBRARY
Patients should not be initiated on Aloflute during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma. | CAVALLINI JAMES/SCIENCE PHOTO LIBRARY

Aloflute is indicated in the regular treatment of asthma in adults aged 18 years and older where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate: 

  • for patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist and
  • for patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist.

Aloflute is available in two strengths each providing 25 micrograms of salmeterol and fluticasone propionate 125 or 250 micrograms per metered dose. Similar products already available in the UK include AirFluSal MDISerefloSeretide Evohaler and Sirdupla.

The recommended dose of Aloflute is two inhalations twice daily. The dose should be titrated to the lowest effective fluticasone dose. As Aloflute is not available in a lower-strength inhaler containing salmeterol 25 microgram and fluticasone propionate 50 microgram, titration down to this level will necessitate a change to another inhaler containing this lower dose of fluticasone.

Prescribers should note that the only spacer recommended for use with Aloflute is the AeroChamber Plus device.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in